Thyroid function during the first year of use of the injectable contraceptive depot medroxyprogesterone acetate

Author(s)

Quintino-Moro, Alessandra ^[1] ; Zantut-Wittmann, Denise Engelbrecht ^[2] ; Silva dos Santos, Priscilla de Nazare ^[1] ; Melhado-Kimura, Vaneska ^[1] ; da Silva, Conceicao Aparecida ^[2] ; Bahamondes, Luis ^[1] ; Fernandes, Arlete ^[1]

Affiliation

^[1] Univ Estadual Campinas, Med Sch UNICAMP, Dept Obstet & Gynecol, Family Planning Clin, Campinas, SP - Brazil

^[2] Univ Estadual Campinas, Med Sch UNICAMP, Dept Internal Med, Div Endocrinol, Campinas, SP - Brazil

• Document type: Journal article
• Source: EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE; v. 24, n. 2, p. 102-108, MAR 4 2019.
• Web of Science Citations: 0

Abstract

Purpose: The aim of the study was to evaluate thyroid function profile as a possible factor influencing weight and body composition variation in new users of depot medroxyprogesterone acetate (DMPA).Materials and methods: A prospective, non-randomised, comparative study was conducted at the University of Campinas, Brazil. Women aged 18-40years with a body mass index (BMI) less than 30kg/m(2), normal oral glucose tolerance test, no known diseases, and using no medication, who opted to use DMPA were paired by age (1year) and BMI (1kg/m(2)) with women initiating copper intrauterine device (IUD) use. The main outcome measures were thyroid function profile, weight, and body composition, as measured by dual-energy X-ray absorptiometry. We used repeated measures ANOVA to perform comparisons between times and groups.Results: We evaluated 28 DMPA users and 24 IUD users who completed the 12-month follow-up. We observed that FT4 levels were higher at 12months (compared to baseline) in the DMPA group (p<.0001) and that FT4/FT3 ratio had increased in both groups. Additionally, at 12months, total body mass had increased around 2kg and lean mass increased in the DMPA group compared to the IUD group; there was also an increase in weight, BMI, total body mass, and fat mass when compared to baseline.Conclusions: No changes in thyroid function occurred that could explain the weight increase observed in DMPA users. (AU)

• FAPESP's process: 09/53293-0 - Prospective study for evaluation of the insulin resistance, lipid metabolism and sub clinical cardiovascular disease in women who initiate the depot-medroxyprogesterone acetate (DMP A) contraceptive method with in follow-up for two years. (Project of scientific research)
• Grantee: Luis Guillermo Bahamondes
• Support Opportunities: Research Grants - Research in Public Policies for the National Health Care System (PP-SUS)